ストックスクリーナーアプリを入手
39.86
0.05%
0.02
前日終値:
$39.84
開ける：
$39.67
24時間の取引高:
431.03K
Relative Volume:
1.10
時価総額：
$2.52B
収益：
-
当期純損益:
$-80.77M
株価収益率:
-31.39
EPS:
-1.27
ネットキャッシュフロー:
$-80.80M
1週間 パフォーマンス:
-0.65%
1か月 パフォーマンス:
-4.57%
6か月 パフォーマンス:
-19.31%
1年 パフォーマンス:
-20.65%
1日の値動き範囲:
$38.50
$41.35
1週間の範囲:
$38.28
$42.27
52週間の値動き範囲:
$36.52
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
MLTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
39.86 | 2.52B | 0 | -80.77M | -80.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2024-11-05 | 再開されました | Wedbush | Outperform |
| 2024-08-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-11-02 | 開始されました | Stifel | Buy |
| 2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 開始されました | Needham | Buy |
| 2023-06-15 | 開始されました | Barclays | Equal Weight |
| 2023-05-01 | 開始されました | Guggenheim | Buy |
| 2023-03-22 | 開始されました | Wedbush | Outperform |
| 2023-03-09 | 開始されました | BTIG Research | Buy |
| 2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 開始されました | Bryan Garnier | Buy |
| 2022-11-11 | 開始されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | SVB Leerink | Outperform |
| 2022-07-21 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by PNC Financial Services Group Inc. - Defense World
BTIG maintains Moonlake stock Buy rating and $81 target By Investing.com - Investing.com Australia
MoonLake Immunotherapeutics’ Sonelokimab Positioned as Leading Treatment for Hidradenitis Suppurativa Amidst Weak JAK Inhibitor Competition - TipRanks
BTIG maintains Moonlake stock Buy rating and $81 target - Investing.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Royal Bank of Canada - Defense World
MoonLake earns new Outperform at RBC Capital Markets on lead drug - MSN
RBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform Recommendation - Nasdaq
MoonLake stock earns new Outperform at RBC (MLTX:NASDAQ) - Seeking Alpha
Why MoonLake Immunotherapeutics Shares Are Rising - TipRanks
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Guggenheim maintains $80 target on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics initiated with an Outperform at RBC Capital - TipRanks
Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target - Marketscreener.com
RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
MoonLake Immunotherapeutics: Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning - TipRanks
MoonLake Immunotherapeutics Advances Clinical Trials in 2024 - TipRanks
MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc. - Defense World
Cowen maintains Buy on Moonlake Immunotherapeutics stock By Investing.com - Investing.com Australia
Cowen maintains Buy on Moonlake Immunotherapeutics stock - Investing.com India
MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases - TipRanks
Why MoonLake Immunotherapeutics is the Dark Horse Pharma Stock to Watch in 2025 - DSA
Optimistic Outlook for MoonLake Immunotherapeutics: Promising Developments and Market Opportunities for Sonelokimab - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
The Goldman Sachs Group Cuts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $73.00 - Defense World
Brokers Offer Predictions for MLTX Q2 Earnings - MarketBeat
MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat
(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily
The Goldman Sachs Group Has Lowered Expectations for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price - MarketBeat
MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Needham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00 - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Earnings Results, Misses Expectations By $0.09 EPS - MarketBeat
MoonLake Immunotherapeutics: Buy Rating Backed by Promising SLK Data and Strong Financial Position - TipRanks
MoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on Thursday - Defense World
Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential - TipRanks
Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals - TipRanks
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position - TipRanks
Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments - TipRanks
MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements - TipRanks
MoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c) - TipRanks
MoonLake Immunotherapeutics Q4 Loss Widens -February 26, 2025 at 07:53 am EST - Marketscreener.com
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss - Marketscreener.com
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
MoonLake Immunotherapeutics SEC 10-K Report - TradingView
Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? - Insider Monkey
This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St
MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
10 Oversold Pharma Stocks to Buy According to Analysts - Insider Monkey
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
Moonlake Immunotherapeutics (MLTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sturge Simon | Director |
Oct 04 '24 |
Sale |
53.72 |
171,000 |
9,186,120 |
171,980 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):